INFLUENCE OF Leu-Ile-Lys-Met THERAPEPTID ON THE KIDNEY FUNCTION AT EXPERIMENTAL OXALATE NEPHROLITHIASIS

Abstract

The study aimed to analyse the effect of the Leu-Ile-Lys-Met tetrapeptide on the function of the kidneys and the formation of renal calculi in rats with experimental 6-week oxalate nephrolithiasis. The experiments were conducted on 20 outbred male Wistar rats 2-3 months old and weighing 250-300 grams, divided equally into 2 groups - comparison (6 weeks of nephrolithiasis modeling) and experimental (6 weeks of nephrolithiasis simulation + daily intragastric administration of Leutetrapeptide) Ile-Lys-Met at a dose of 12 mg/kg from 4 to 6 weeks). Oxalate nephrolithiasis was modelled using a conventional ethylene glycol model. Before starting nephrolithiasis modelling, and then every 7 days in urine, biochemical parameters of renal function were determined: diuresis, creatinine excretion and activity of marker enzymes of nephrothelial damage - lactate dehydrogenase and γ-glutamyltransferase. After 6 weeks of the experiment, the rats were euthanized under ether anaesthesia and kidneys were removed for morphological assessment of the degree of intensity of stone formation. It was established that the level of diuresis in both groups throughout the experiment remained stable and did not differ between the groups. Creatinine excretion in the comparison group by the end of the experiment decreased by 2 times (p = 0,017), and remained stable in the experimental group. The activity of lactate dehydrogenase and γ-glutamyltransferase in the experimental group by the end of treatment was significantly lower than the level of the comparisons group. Thus, it was found that the three-week use of the Leu-Ile-Lys-Met tetrapeptide in experimental oxalate nephrolithiasis normalizes renal function and weakens nephrocyte damage, which is accompanied by the absence of signs of stone formation in the kidneys.